Evidence map›Paper›PMID 32937177›Full record

ReviewPharmacological research2020

Prokineticin signaling in heart-brain developmental axis: Therapeutic options for heart and brain injuries.

Laurent Désaubry, Anumantha G Kanthasamy, Canan G Nebigil

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Laurent DésaubryRegenerative Nanomedicine, UMR 1260, INSERM, University of Strasbourg, Strasbourg, France.
Anumantha G KanthasamyParkinson's Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, Iowa, USA.
Canan G NebigilRegenerative Nanomedicine, UMR 1260, INSERM, University of Strasbourg, Strasbourg, France. Electronic address: nebigil@unistra.fr.
Iowa State University · USRegenerative NanoMedicine · FRUniversité de Strasbourg · FR

Funding

Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.R01ES026892 · NIEHS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2016 to 2020
$2.0M
Neuroinflammation and microglial Kv1.3 in Parkinsons diseaseR01NS100090 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2017 to 2021
$1.9M
Role of Prokineticin 2 in Metal NeurotoxicityR01ES034196 · NIEHS · UNIVERSITY OF GEORGIA · PI ARTHI KANTHASAMY, Anumantha Gounder Kanthasamy · 2023 to 2026
$1.7M
Exosomes and Neuroinflammation in Parkinsons DiseaseR01NS088206 · NINDS · IOWA STATE UNIVERSITY · PI KANTHASAMY, ARTHI · 2015 to 2019
$1.6M
NIEHS NIH HHS R01 ES026892NIEHS NIH HHS R01 ES034196NINDS NIH HHS R01 NS088206NINDS NIH HHS R01 NS100090
6 · The paper itself

Abstract

Heart and brain development occur simultaneously during the embryogenesis, and both organ development and injuries are interconnected. Early neuronal and cardiac injuries share mutual cellular events, such as angiogenesis and plasticity that could either delay disease progression or, in the long run, result in detrimental health effects. For this reason, the common mechanisms provide a new and previously undervalued window of opportunity for intervention. Because angiogenesis, cardiogenesis and neurogenesis are essential for the development and regeneration of the heart and brain, we discuss therein the role of prokineticin as an angiogenic neuropeptide in heart-brain development and injuries. We focus on the role of prokineticin signaling and the effect of drugs targeting prokineticin receptors in neuroprotection and cardioprotection, with a special emphasis on heart failure, neurodegenerativParkinson's disease and ischemic heart and brain injuries. Indeed, prokineticin triggers common pro-survival signaling pathway in heart and brain. Our review aims at stimulating researchers and clinicians in neurocardiology to focus on the role of prokineticin signaling in the reciprocal interaction between heart and brain. We hope to facilitate the discovery of new treatment strategies, acting in both heart and brain degenerative diseases.

Indexed as

AnimalsBrainBrain DiseasesHeartHeart DiseasesHumansNeurogenesisReceptors, G-Protein-CoupledVascular Endothelial Growth Factor, Endocrine-Gland-DerivedPROKR1 protein, humanReceptors, G-Protein-CoupledVascular Endothelial Growth Factor, Endocrine-Gland-DerivedAngiogenesisBrainGPCRHeartHeart failureNeuropeptideParkinsonProkineticinRegeneration

Identifiers

PMID32937177
PMCPMC7674124
OpenAlexW3086421591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.